Natco stock rides Copaxone generic 'probability' wave
This article was originally published in Scrip
Pure speculation or some substance no one seemed very sure, but shares of Natco surged to a 52-week high on Indian bourses amid expectations that new launches in the US, including a much awaited generic version of Teva's multiple sclerosis blockbuster Copaxone (glatiramer acetate), would power the Indian firm's sales during the year.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.